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E-mail address: rolandliblau@hotmail.com (R.S. LibMultiple sclerosis (MS) is an immune-mediated disease of the central nervous system leading to
demyelination and axonal/neuronal loss. Cumulating evidence points to a key role for CD8 T cells
in this disabling disease. Oligoclonal CD8 T cells reside in demyelinating plaques where they are
likely to contribute to tissue destruction. Histopathological analyses and compelling observations
from animal models indicate that cytotoxic CD8 T cells target neural cell populations with the
potential of causing lesions reminiscent of MS. However, CD8 T cell differentiation results in several
subsets of effector CD8 T cells that could be differentially implicated in the mechanisms contribut-
ing to tissue damage. Moreover CD8 regulatory T cells arise as important populations involved in
restoring immune homoeostasis and in maintaining immune privileged sites. Here we examine
the current literature pertaining to the role of CD8 effector and regulatory T cell subsets in the path-
ogenesis of MS.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Multiple sclerosis (MS) is an inﬂammatory demyelinating dis-
ease of the central nervous system (CNS) [1]. This disabling disease
is characterized by multi-focal demyelination, axonal loss, activa-
tion of glial cells and inﬁltration by immune cells [1]. During the
early phases of lesion formation CD4 and CD8 T cells, aswell asmac-
rophages, are recruited to the CNS white matter. The antigens that
trigger this immune response to cause tissue damage are currently
unknown but may includemyelin self-antigens [1,2]. The predispo-
sition to MS is in part genetically determined. The strongest known
genetic risk-factor is the DRB11501–DQB10602 haplotype which
encodes for the human leukocyte antigen (HLA)-DR2 and DQ6mol-
ecules, thus implicating HLA class II molecules and CD4 T cells inMS
pathogenesis [3,4]. Nevertheless, treatment of relapsing-remitting
MS patients with a depleting anti-CD4 antibody did not alleviate
relapse rate, neither progression of new lesions [5,6], in contrastcal Societies. Published by Elsevier
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lau).depleting all lymphocyte populations, signiﬁcantly reduced relapse
rate and new lesion formation [7].
Among the additional lymphocytic populations CD8 T cells are
emerging as important effector cells in MS. Recent genetic studies
strongly advocate an independent association between speciﬁcma-
jor histocompatibility complex (MHC) class I alleles andMS [8]. The
exact contribution of CD8 T cells in the pathogenesis of MS remains
ambivalent as the HLA-A0301 allele is reported to increase suscep-
tibility [9,10], whereas the HLA-A0201 allele confers protection
from the disease [4,11]. This review discusses the recent advances
regarding functionally distinct CD8 T cell subsets and their implica-
tion in the pathogenesis of MS.
2. Effector CD8 T cell subsets in MS and its animal models
2.1. Generalities on CD8 T cells and their subsets
CD8 T cells are essential players of the adaptive immune sys-
tem. Their intrinsic ability to perceive very few peptide–MHC class
I complexes and thereby mediate direct killing of antigen-present-
ing target cells underlie their capacity to provide defense against
intracellular pathogens [12].
Sallusto et al. described different subsets of CD8 T cells in
human peripheral blood based on the expression of CD45RA and
the chemokine receptor CCR7: (i) a CD45RA+ CCR7+ subset,
composed of naive cells that lack effector functions, (ii) aB.V. Open access under CC BY-NC-ND license.
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cells without active effector function, also referred to as ‘‘central
memory’’ (TCM), (iii) a CD45RA, CCR7memory cell subset, which
bears effector functions, termed ‘‘effector memory’’ (TEM), (iv) a
CD45RA+, CCR7 subset that includes highly differentiated, anti-
gen-experienced cells with effector functions (TEff) [13].
In order to acquire effector functions naive CD8 T cells undergo a
series of events which include recognition of peptide:MHC class I
complexes on antigen-presenting cells, co-stimulatory signals pro-
videdbyCD28–B7 interaction inpresenceof inﬂammatory cytokines
leading to activation, proliferation and differentiation into a hetero-
geneous pool of effector CD8 T cells [12,14,15]. The commitment of
naïveT cells to functionally distinct subsets is dictatedby thecompo-
sitionof the local cytokinemilieu. The inﬂuence of cytokine signaling
on thedifferentiationof CD8T cells resembles that of their CD4 coun-
terparts. For instance, T-bet expression is induced by IL-12 for Tc1
differentiation, GATA-3 is induced by IL-4 for Tc2 differentiation
[16]. It has recently been shown that the IL-17-producing subset of
CD8 T cells (Tc17) follows a similar differentiation program as
Th17cells [17]. Th17cell differentiation requires retinoid-relatedor-
phan receptor (ROR)ct, a transcription factor that is induced by TGF-
b in combination with the pro-inﬂammatory cytokines IL-6, IL-21
and IL-23 [18]. Taken together, these ﬁndings suggest that the local
microenvironment, through provision of speciﬁc cytokines, directs
the multiple possible alternate fates that CD8 T cells can adopt.
Differentiated subsets of CD8 T cells acquire distinct migratory
properties to survey extra lymphoid tissues [19]. Moreover,
cytotoxic CD8 T lymphocytes (CTLs) may acquire a distinct
tissue-speciﬁc phenotype. For instance, T cells isolated from the
skin uniquely express E-selectin and CCR4, while T cells isolated
from the small intestine express CCR9 and the a4b7 integrin
[20]. Several studies have demonstrated that the tissue environ-
ment and the local dendritic cells themselves imprint this tissue-
speciﬁc signature to the T cells [20–22]. This differential homing
potential associated with distinct effector functions advocates that
the antigen-driven diversiﬁcation of the CD8 T cell response is in-
structed rather than stochastic, implicitly questioning the role of
these CD8 T cell subsets in immune-mediated diseases, such as MS.
Effector CD8 T cells use both cytotoxic and non-cytotoxic func-
tions to affect their target cells: (i) cytotoxic molecules such as
granzyme and perforin mediate direct contact-dependent cytotox-
icity [23], (ii) expression of Fas ligand (CD95L) induces apoptosis in
a Fas–Fas ligand dependent manner [23] and (iii) immediate secre-
tion of pro-inﬂammatory cytokines, including IFN-c and TNF-a,
sustains local inﬂammation [24].
2.2. CD8 T cells and their subsets in MS
Although the implication of CD4 T cells in the pathogenesis ofMS
has been largely investigated, several arguments support a key role
for CD8Tcells. The independent associationbetween theMHCclass I
allele HLA-A0301 and MS susceptibility argues for a potential role
of MHC class I-restricted CD8 T cells in MS pathogenesis. However,
the contribution of CD8 T cells in MS is likely complex as the HLA-
A0201 allele confers signiﬁcant protection from the disease (see
Fig. 1).
Most CNS resident cells such as astrocytes, oligodendrocytes and
neurons do expressMHC class I molecules, at least under inﬂamma-
tory conditions, making them potential targets for CD8 T cells.
Moreover, up-regulation of MHC class I molecules can be observed
early during the course of MS, before demyelination develops
[25–27]. Furthermore, activated microglial cells have been shown
to cross-present exogenous peptides on MHC-I molecules, thereby
supporting the persistence and expansion of the CD8 T cell response
[28].In post-mortem material from acute or relapsing-remitting MS
patients, CD8 T cells are consistently detected within perivascular
cuffs and parenchymal lesions [29] where they frequently outnum-
ber CD4 T cells [30–33]. Within parenchymal lesions cytotoxic T
cells can be detected with their cytolytic granules polarized to-
wards demyelinated axons indicative of imminent T cell mediated
killing [34]. Furthermore, there is a positive correlation between
the abundance of CD8 T cells and the intensity of axonal damage
[35,36].
TcR usage analyses of CNS-inﬁltrating CD8 T cells have revealed
oligoclonal expansion of CD8 T cells within MS lesions [30,33] and
the CSF [37], suggesting an antigen-driven activation of CD8 T cell
clones during the course of MS. Moreover, CDR3 nucleotide se-
quences encoding TcRs isolated from different lesions of individual
MS brains revealed silent nucleotide changes implying that distinct
T cell clones with identical antigen-speciﬁcity can be detected
within MS lesions [33]. This CDR3 spectratyping conﬁrms that
inﬁltration of CD8 T cells in the lesions is selective, rather than sto-
chastic. Collectively, these data suggest that CD8 T cell clones with
shared speciﬁcity have trafﬁcked to the CNS independently and
have responded locally to a given set of antigens.
In blood, even though myelin-speciﬁc CD8 T cells lines could be
derived fromMSpatients aswell as healthy controls [38–41], a high-
er frequency of CD8 T cells recognizingmyelin proteins has been re-
ported inMS patients [41,42]. These data are however controversial
[43]. MBP-speciﬁc CD8 T cells clones isolated from MS patients, as
well as healthy individuals, secrete the pro-inﬂammatory cytokines
IFN-c and TNF-a and speciﬁcally lyse freshly isolated HLA-matched
human oligodendrocytes, without the addition of exogenous pep-
tide [44]. These observations however are either ‘‘unique’’ or follow
strong in vitro manipulation of cell lines, which might have inﬂu-
enced their functional properties. An unbiased approach determin-
ing the nature and phenotype of the CNS-inﬁltrating CD8 T cells in
MS is highly needed.
A recent report argues for IL-17-producing CD8 T cells (Tc17)
being involved in MS pathogenesis [45]. This is based on the obser-
vation that the vast majority of the CD4 and CD8 T cells detected in
the perivascular spaces of active MS lesions were labeled for IL-17
by immunohistology and in situ hybridization. In contrast, inactive
lesions contained only few IL-17-producing T cells [45]. Further-
more, Annibali et al. have identiﬁed signiﬁcant up-regulation of
natural killer receptor protein 1a/CD161 and increased numbers
of CD161high CD8 T cells in the peripheral blood of MS patients
[46]. This subset of CD8 T cells includes most of the CCR6+, effector
memory T cells with pro-inﬂammatory properties. Interestingly,
CCR6 has been implicated in the transmigration of T cells into
the uninﬂamed CNS through the choroid plexus [47].
Moreover, all the circulating Tc17 cells are contained within
this CD161high subset, further suggesting a role for this subset of
CD8 T cells in MS pathogenesis [46]. It is at present unclear
whether these CD161high CD8 T cells are conventional HLA class
I-restricted T cells or whether they belong to an innate-like T cell
subset.
Recent studies revealed enrichment of activated effector mem-
ory CD8 T cells in CSF [48]. These effector memory CD8 T cells do
not express CCR7 [49] and can therefore be retained in the tissue
and carry out their effector functions [13,50,51]. Moreover, en-
riched numbers of CCR7 CD45RA+/ CD8 T cells has been shown
in the CSF of early-diagnosed MS patients suggesting that CD8 T
cells are implicated early on in the development of relapsing-
remitting MS [48].
Altogether these ﬁndings converge to support the concept of a
pathogenic role for CD8 T cells in MS. However, association is not
causation and the ﬁnal proof of their pathogenic involvement is
still lacking.
Fig. 1. Hypothetical scheme of the contribution of CD8 T cells in MS pathogenesis. Numerous genetic and environmental factors modulate the immune response so that
dendritic cells (DCs) productively present self-antigens to autoreactive T cells. These autoreactive T cells differentiate into different effector subsets. CD8 T cells differentiate
into regulatory and effector (including CTLs) subsets that can transmigrate into the CNS through the BBB. Microglia and recruited macrophages (M/) present self-
peptide:MHC-I complexes and promote clonal expansion of autoreactive CTLs. These activated CTLs directly target MHC-I expressing oligodendrocytes and axons/neurons,
leading to irreversible tissue damage. Chemokines and cytokines produced by effector CD8 T cells contribute to sustain the inﬂammatory reaction. Regulatory CD8 T cells may
play a major role in the pathogenesis of MS by directly killing pathogenic CD4 T cells in an HLA-E-dependent manner, therefore reducing CNS inﬂammation and promoting
remission.
3760 A. Saxena et al. / FEBS Letters 585 (2011) 3758–37632.3. CD8 T cells in animal models of MS
To better understand the functional contribution of CD8 T cells
in CNS tissue damage, several experimental models were gener-
ated. Among the virally induced models, the Theiler’s murine
encephalomyelitis virus (TMEV) mouse model reproducing several
histological features of MS. Indeed, the intra-cerebral injection of
TMEV in susceptible mouse strains (SJL) elicits chronic inﬂamma-
tory demyelinating lesions, involving macrophagic and lympho-
cytic inﬁltration, degradation of myelin, axonal damage and
gliosis. Both CD8 and CD4 contribute to the disease process; CD8
T cells by killing of infected oligodendrocytes and CD4 T cells
through bystander mechanisms in response to viral and myelin
antigens [52,53]. However, in resistant mouse strains (C57Bl/6),
the infection is cleared within 3 weeks by a strong anti-viral CD8
T cells response that controls viral spread by both lytic and non-ly-
tic mechanisms. Effector CD8 T cells can use these mechanisms to
target resident CNS cells [9,54,55].
Much emphasis has been put recently on the contribution of
CD8 T cells in animal models of CNS autoimmunity. Huseby et al.
have demonstrated that adoptive transfer of H-2Kk-restricted
CD8 T cells speciﬁc for MBP79–87 induces clinical experimental
autoimmune encephalomyelitis (EAE) in C3H mice, reproducing
features of MS lesions usually not observed in CD4 T cell-driven
EAE [56]. Furthermore, adoptive transfer of MOG35–55 speciﬁc
CD8 T cells induces progressive EAE in C57BL/6 mice, independent
of CD4 T cells [57]. The adoptive transfer of H-2Db-restricted CD8 T
cells speciﬁc for the short MOG37–46 peptide also induces EAE intoC57Bl/6 recipients [58]. Therefore, MOG35–55 is thought to contain
at least 2 nested encephalitogenic epitopes: MOG40–48 that elicits a
CD4 T cell response in the context of H-2I-Ab [59], and MOG37–46
inducing a CD8 T cell response restricted to H-2Db [58]. Most re-
cently, MOG42–50 was found to bind to H-2Db molecule to elicit a
CD8 T cell responses in MOG-deﬁcient animals. However, CD8+ T
cells responsive to this MOG peptide could neither initiate CNS
inﬂammation upon passive transfer nor exacerbate EAE once it is
underway in MOG-expressing animals [60].
To further investigate the damage caused by CD8 T cells recog-
nizing an oligodendroglial antigen, we developed an original mur-
ine model. This transgenic model combines the MOG-HA mice,
expressing the Inﬂuenza virus hemagglutinin (HA) selectively in
oligodendrocytes using the MOG promoter, with TcR-transgenic
mice expressing an H-2Kd-restricted HA512–520-speciﬁc TcR on
most CD8 T cells [61,62]. The adoptive transfer of HA-speciﬁc Tc1
cells in MOG-HA mice induces inﬂammatory lesions in the optic
nerve, spinal cord, and brain. These lesions associate CD8 T cell
inﬁltration with focal loss of oligodendrocytes, demyelination, ax-
onal damage, and microglia activation, features that are very rem-
iniscent of active MS lesions [62]. A similar transgenic model
introduced ovalbumin (OVA) under the proximal MBP promoter
(ODC-OVA mice) to induce the expression of a neo-self antigen in
the cytosol of oligodendrocytes. Crossing these mice with mice
expressing H-2Kb-restricted OVA257–264-speciﬁc TcR on CD8 T cells
(OT-1 mice) induces a spontaneous disease characterized by
noxious demyelinating lesions [63] that combine the speciﬁc loss
of oligodendrocytes with bystander damage to axons [64]. CD8
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blocking antigen presentation of OVA257–264 through administra-
tion of a monoclonal antibody speciﬁc for the H-2Kb:OVA257–264
complex [65]. These ﬁndings document the nature of the CNS
tissue damage mediated by CD8 T cells speciﬁc for a sequestered
self-antigen expressed by oligodendrocytes.
In addition, humanized mouse models have served as a cutting
edge tool to study the functional relevance of human MHC class I
genes [8]. To this goal, murine MHC class I expression has been
invalidated to impose the restriction of the CD8 T cell repertoire
to transgenic human HLA class I molecules. To gain insight into
the functional relevance of HLA-A3 in MS pathogenesis, humanized
transgenic mice expressing both HLA-A0301 and an HLA-
A0301:PLP45–53-speciﬁc TcR (2D1) isolated fromMS patients were
generated [66]. A small fraction (4%) of these humanized mice
developed spontaneous EAE driven by CD8 T cells. PLP45–53 immu-
nization in complete Freund adjuvant induces mild disease in 71%
of these mice, followed in 25% of them by a severe disease leading
to hind limb paralysis. The PLP45–53-speciﬁc CD8 T cells mediate
the ﬁrst phase of this disease, whereas the second phase is due
to CD4 T cells targeting the MOG35–55 epitope in the context of
the murine I-Ab molecule [66]. Therefore, this study demonstrates
that CD8-driven autoimmune demyelination can initiate epitope
spreading. We have shown in a transgenic mouse model that
HLA-A2-restricted autoreactive CD8 T cells recognizing MOG181–
189 could worsen the outcome of MOG35–55-induced EAE [67]. Con-
versely, humanized mice expressing the 2D1 TcR along with the
disease protective HLA-A2 molecule were completely protected
from both spontaneous and active EAE due to thymic negative
selection of 2D1-expressing developing CD8 T cells induced by
HLA-A2 [66]. The hypothesis that the MS-protective effect of
HLA-A0201 is related to negative selection of myelin-reactive
CD8 T cells is appealing but would need to be tested for other
clonotypes.
These studies document that autoreactive CD8 T cells are detri-
mental in animal models of MS, further advocating their potential
contribution in MS pathogenesis.3. Regulatory CD8 T cells
3.1. Generalities
Regulatory T cells (Tregs) play an essential role in contending
immunological unresponsiveness to self-antigens and in suppress-
ing excessive immune responses deleterious to the host [68]. Sev-
eral subsets of natural CD8 Tregs have been identiﬁed based on the
expression of CD25 [69], FoxP3 [70,71], CD122 [72] and/or HLA-G
[73], or lack of CD28 expression [74]. CD8+CD122+ abTCR Tregs
could sense activated T cells by interacting with cell surface mole-
cules including classical MHC class I [75] and directly constrain
proliferation and IFN-c production of CD8 T cells presumably via
production of IL-10 [76]. Moreover, in human peripheral blood a
novel immunoregulatory population was identiﬁed among CD4
and CD8 T cells expressing HLA-G in the absence of FoxP3. This
population exhibits potent suppressive properties that are partially
mediated by HLA-G, immunoglobulin-like transcript-2 (ILT-2) and
IL-10 [73,77]. In addition, Mayer et al. showed that CD8+FoxP3+ T
cells have reduced suppressive activity while they share develop-
mental and phenotypic features with CD4+FoxP3+ Tregs [78]. Fur-
thermore, a population of CD8+CD28 cells has the capacity to
suppress immune responses by directly interacting with APCs
and rendering them tolerogenic [74]. Menager-Marcq et al. demon-
strated that naturally occurring CD8+CD28 Tregs can block gut
inﬂammation by the secretion of IL-10 in a murine model of
inﬂammatory bowel disease [79]. In human, CD8+CD28 T cellstrigger the up-regulation of ILT-3 and ILT-4 on monocytes and den-
dritic cells, which was responsible for the propagation of antigen-
speciﬁc CD4 Treg mediated suppression [80,81]. A regulatory sub-
set of TCRa/b CD8 T cells has been shown to recognize activation-
induced peptides (Vb peptides, HSP60) in the context of Qa-1, a
non-classical MHC class Ib molecule [82]. Their positive selection
in the thymus requires interaction with Qa-1, which can be pro-
vided by hematopoietic, rather than epithelial cells [83]. Qa-1-re-
stricted CD8 T cells appear to control secondary, rather than
primary, CD4 T cell responses. These Qa-1-restricted CD8 Tregs
could control effector CD4 T cells through several mechanisms: di-
rect killing of CD4 T cells and/or inactivation of APCs. Recently, Qa-
1-restricted CD8 T cells have been shown to maintain self-toler-
ance primarily through elimination of follicular helper CD4 T cells,
which, upon activation, express high levels of Qa-1 [84]. The inte-
grin aEb7 (CD103) has been identiﬁed as a marker for alloreactive
induced CD8 Tregs. When exposed to alloantigens and expanded
in vitro CD8+CD103+ T cells produced signiﬁcant quantities of IL-
10 and suppressed T-cell proliferation through a cell contact
dependent mechanism, even though their cytotoxic potential was
limited [85,86].
3.2. CD8 Tregs in MS and its animal models
The immunoregulatory functions of CD8 T cells have been stud-
ied during the course of EAE. Based on antibody-mediated deple-
tion experiments, CD8 T cells were found to be a major factor in
the resistance to a second induction of EAE after recovery from
the ﬁrst episode [87]. Various regulatory CD8 T cell subsets could
account for this impact. Mice knock-out for the non-classical
MHC class Ib molecule Qa-1 exhibit little aggravation of EAE sever-
ity, but are more susceptible to EAE re-induction following initial
suboptimal PLP immunization, again pointing at an inhibitory ef-
fect role of Qa-1-restricted CD8 T cells on secondary responses
[88]. Interestingly, Qa-1-restricted T cells elicited by a previous
expansion of Vb8.2+ CD4 T cells directed to a foreign antigen can
also inhibit EAE mediated by Vb8.2+ MOG-speciﬁc CD4 T cells
[89]. Naturally occurring CD8+CD122+ Tregs produce IL-10 and
suppress IFN-c production and T-cell proliferation. In vivo deple-
tion of these cells by anti-CD122 mAb in MOG35–55 immunized
mice increases the duration of EAE, while the adoptive transfer of
puriﬁed CD8+CD122+ T cells at the peak of disease provide clinical
beneﬁt [90]. Furthermore, CD8 Tregs actively contribute to the
resistance of CD28/ to CNS autoimmunity [74]. Indeed, both
depletion of CD8 T cells and CD8 gene invalidation restore suscep-
tibility of CD28/ mice to MOG35–55-induced EAE. Resistance to
EAE is restored by the adoptive transfer of CD8+ CD28 T cells in
CD8/mice, demonstrating their regulatory function in vivo [74].
Several studies have pointed out that MS could be favored by an
impaired suppressive function of Tregs, including CD8 Tregs [91–
93]. More recently, a study pointed out that CD8 T cell clones iso-
lated from MS patients can kill myelin-speciﬁc CD4 T cells using a
mechanism dependent on HLA-E, the human homolog of mouse
Qa-1 [94]. However, HLA-E can also interact with CD94/NKG2
receptors expressed on CD8 T cells and this interaction can inhibit
CD8 T cell cytotoxicity. In MS patients, a signiﬁcantly elevated
expression of CD94/NKG2 on CD8 T cells was observed during clin-
ical exacerbation, presumably inhibiting the killing of pathogenic
CD4 T cells [94]. The suppressive function of HLA-E-restricted
CD8 T cells was also observed in MS patients treated with glatir-
amer acetate (GA, Copaxone), a pool of synthetic polypeptides
with immunomodulatory properties [95]. CD8 Tregs from treated
MS patients express high levels of perforin and could kill GA-reac-
tive CD4 T cells in a cell contact dependent mechanism. This sup-
pressive activity of GA-induced CD8 Treg is directly correlated
with clinical remission [96,97].
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CD8 Tregs, could also be involved in the MS pathogenesis. These
cells accumulate at sites of inﬂammation during relapses of MS
and can suppress either CD4 or CD8 T cell responses through a con-
tact-independent mechanism. These patients uniformly show
higher frequencies of HLA-G-expressing cells in the CSF as com-
pared to peripheral blood [73,77]. Furthermore, Airas et al. pointed
out that a drop in the number of HLA-G expressing CD4 and CD8 T
cells is associated with an increased risk of postpartum relapses in
females with MS [98].
These studies clearly point out that, although FoxP3+CD4+ Tregs
are essential regulators of the immune system, certain CD8 T cell
populations possess immunoregulatory functions that might inﬂu-
ence the progression of MS.
4. Concluding remarks
Effector CD8 T cells may have a major detrimental effect in MS,
given their unique ability to recognize self-peptides presented by
MHC class I molecules on almost any nucleated cell type. Experi-
mental models serve as cutting edge tools to assess the potential
of these effector CD8 T cells to mediate tissue damage and to inves-
tigate the mechanisms involved. There is also evidence to suggest a
regulatory function of CD8 T cells during the course of MS. Given
these opposite functions that CD8 T cells may carry in MS, it is
essential to better characterize the various subsets of CD8 T cells,
identify speciﬁc markers, and investigate their changes as disease
evolves. In addition, understanding their speciﬁc function and anti-
gen speciﬁcity will be helpful to uncover the role of these CD8 T
cell subsets in MS pathogenesis.
Several fundamental questions remain to be addressed. How do
pathogenic CD8 T cells become activated to target ‘self’? Do they
follow the same rules as CD4 T cells for activation and migration
into the CNS? How are the autoreactive CD8 T cell responses regu-
lated and how do these mechanisms fail in MS patients? How do
the genetic polymorphisms associated with MS [4] alter the biol-
ogy of CD8 T cells?
Most current therapies in MS have been designed to target
pathogenic CD4 T cells. There is however little doubts that they
also impact on other immune cell subsets such as the CD8 T cells.
A better understanding of the pathogenic and regulatory potential
of CD8 T cells may help develop more focused therapeutic strate-
gies for MS.
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